Literature DB >> 313804

Release of soluble "blocking" and "suppressor" factors from normal lymphocytes treated with RNA from spleens of tumour-bearing mice.

K J Pennline, S B Evans, J F Nawrocki, J C Rees, C S Johnson, D A Vallera, M C Dodd.   

Abstract

RNA extracted from the spleens of tumour-bearing (TLRNA) and tumour-immune (ILRNA) mice was shown to transfer to normal lymphocytes (NL) the ability to produce factors that blocked specific tumour-cell cytotoxicity and mediated specific antibody-dependent cell cytotoxicity (ADCC). Aliquots of normal C3H mouse lymphocytes were treated with TLRNA or ILRNA and cultured in vitro in the absence of tumour antigen. Supernatants were collected at 24h intervals and tested in a microcytotoxicity assay for blocking and ADCC activities. Factors that inhibited tumour destruction by specifically sensitized lymphocytes at the level of both the tumour cells and effector cells were demonstrable in culture supernatants of NL pretreated with TLRNA (50 or 100 microgram/4 X 10(6) cells) but not ILRNA. However, treatment of NL with either RNA resulted in the production factors that mediated tumour-specific ADCC. Cytotoxicity testing and absorption studies of the tumour cell and a control cell (LM) indicated that factors mediating ADCC and blocking at the target-cell level were specific for the tumour. Suppressor activity at the effector-cell level was not absorbed by tumour cells and represents a separate and distinct mechanism of immunosuppression. These data indicate that RNA faithfully transfers "suppressive" as well as "positive" types of immune responses that have been reported previously for lymphocytes obtained directly from tumour-bearing and tumour-immune animals.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 313804      PMCID: PMC2009868          DOI: 10.1038/bjc.1979.48

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  TRANSFER OF HEIGHTENED IMMUNITY TO SKIN HOMOGRAFTS BY LYMPHOID RNA.

Authors:  J A MANNICK; R H EGDAHL
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  THE ROLE OF THYMUS IN TRANSPLANTATION RESISTANCE INDUCED BY POLYOMA VIRUS.

Authors:  R C TING; L W LAW
Journal:  J Natl Cancer Inst       Date:  1965-04       Impact factor: 13.506

3.  Propagation of strain L (Earle) cells in agitated fluid suspension cultures.

Authors:  R J KUCHLER; D J MERCHANT
Journal:  Proc Soc Exp Biol Med       Date:  1956 Aug-Sep

4.  Expression of various tumor-specific antigens in polyoma virus-induced tumors.

Authors:  C C Ting; D H Lavrin; K K Takemoto; R C Ting; R B Herberman
Journal:  Cancer Res       Date:  1972-01       Impact factor: 12.701

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  'Immune' RNA-mediated transfer of delayed skin reactivity in patients with Hodgkin's disease.

Authors:  T Han
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

7.  The role of blocking antibodies in immunological enhancement.

Authors:  M Takasugi; E Klein
Journal:  Immunology       Date:  1971-10       Impact factor: 7.397

8.  Mediation of immune responses to tumor antigens in vitro by immune RNA.

Authors:  D H Kern; C R Drogemuller; Y H Pilch
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

9.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

10.  Anti-tumour cytotoxicity of poly(A)-containing messenger RNA isolated from tumour-specific immunogenic RNA.

Authors:  C J Greenup; D A Vallera; K J Pennline; B J Kolodziej; M C Dodd
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.